For the year ending 2025-12-31, CODX had $8,948,063 increase in cash & cash equivalents over the period. -$29,836,974 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -46,895,936 |
| Depreciation and amortization | 1,106,808 |
| Impairment charges | 18,882,000 |
| Stock-based compensation expense | 2,248,053 |
| Common stock issued for financial advisory services | 135,000 |
| Change in fair value of acquisition contingencies | 805,863 |
| Non-cash lease expense | -8,197 |
| Realized gain on investments | 683,365 |
| Loss from equity method investment | -46,301 |
| (gain) loss on disposition of assets | -82,421 |
| Recoveries of credit losses | 26,006 |
| Inventory obsolescence expense (recovery) | -50,944 |
| Accounts receivable | 31,799 |
| Prepaid expenses and other assets | -585,926 |
| Inventory | -131,271 |
| Deferred revenue | -26,057 |
| Income taxes payable | -713,643 |
| Accounts payable, accrued expenses and other liabilities | -3,112,897 |
| Net cash used in operating activities | -29,136,927 |
| Purchases of property and equipment | 700,047 |
| Proceeds from maturities of marketable investment securities | 33,666,959 |
| Purchases of marketable securities | 6,590,939 |
| Investment in joint ventures | 102,566 |
| Net cash provided by investing activities | 26,273,407 |
| Proceeds from exercise of options | 12,500 |
| Issuance of common stock related to at-the-market offering, net of offering costs | 1,810,813 |
| Issuance of common stock related to registered direct offering, net of offering costs | 9,988,270 |
| Net cash provided by financing activities | 11,811,583 |
| Net increase (decrease) in cash and cash equivalents | 8,948,063 |
| Cash and cash equivalents at beginning of period | 2,936,544 |
| Cash and cash equivalents at end of period | 11,884,607 |
Co-Diagnostics, Inc. (CODX)
Co-Diagnostics, Inc. (CODX)